BioAtla, Inc.
BCAB
$4.54
$0.020.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -16.19% | -30.29% | |||
| Gross Profit | 37.15% | 30.29% | |||
| SG&A Expenses | -23.29% | -14.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.38% | -26.05% | |||
| Operating Income | 32.88% | 26.05% | |||
| Income Before Tax | 37.99% | 15.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 37.99% | 15.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.99% | 15.68% | |||
| EBIT | 32.88% | 26.05% | |||
| EBITDA | 32.75% | 25.90% | |||
| EPS Basic | 39.08% | 16.02% | |||
| Normalized Basic EPS | 39.08% | 16.02% | |||
| EPS Diluted | 39.08% | 16.02% | |||
| Normalized Diluted EPS | 39.08% | 16.02% | |||
| Average Basic Shares Outstanding | 1.79% | 0.41% | |||
| Average Diluted Shares Outstanding | 1.79% | 0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||